Orthocell gets approval from Europe for its regenerative medicine, its shares soar

Sean Gallup/Getty Images

Shares in Orthocell jumped after the medtech gained approval to sell its dental bone and soft tissue regeneration solution in Europe.

The company came out of a trading halt and the shares took off. A short time ago, they were 16% higher at $0.36.

The Perth-based regenerative medicine company announced European regulatory approval for its CelGro collagen medical device.

“This provides a strong foundation for Orthocell to progress additional dental regulatory applications in key markets, such as the US, Japan and Australia,” says Orthocell Managing Director Paul Anderson.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.